The misuse of extended-release and long-acting (ER/LA) opioids is a major public health problem. Centers for Disease Control and Prevention reported the following:

• From 2000 to 2015 more than half a million people died from drug overdoses.
• 91 Americans die every day from an opioid overdose.

The CO*RE/ASAM Pain Management and Opioids: Balancing Risks and Benefits addresses the opioid public health crisis. This comprehensive course was developed by renowned experts from Collaborative for REMS Education (CO*RE) and incorporates all six units outlined in FDA blueprint for safe opioid prescribing. The updated course also provides necessary context for safe opioid prescribing by discussing biopsychosocial aspects of pain, the newest clinical guidelines on the treatment of chronic pain, and state policies about prescribing opioids.

Learners will be able to:

1. Accurately assess patients with pain for consideration of an opioid trial
2. Establish realistic goals for pain management and restoration of function
3. Initiate opioid treatment (IR and ER/LA) safely and judiciously, maximizing efficacy while minimizing risks
4. Monitor and re-evaluate treatment continuously; discontinue safely when appropriate
5. Counsel patients and caregivers about use, misuse, abuse, diversion, and overdose
6. Educate patients about safe storage and disposal of opioids
7. Demonstrate working knowledge and ability to access general and specific information about opioids, especially those used in your practice.

CME Information and Disclosure Listing

The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. ASAM has been awarded the highest level of Accreditation with Commendation by the ACCME as a provider of continuing medical education.  

The American Society of Addiction Medicine designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

In accordance with the disclosure policies of the American Society of Addiction Medicine (ASAM) and the Accreditation Council for Continuing Medical Education (ACCME), the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the Medical Education Council, the CME Committee, program planning committees and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of the activity. All program planning committee members and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The ASAM CME Committee has reviewed these disclosures and determined that the program planning committee and faculty relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.  

ASAM CME Committee

Program Planning Committee

Faculty

  ASAM CME Committee Reviewers

ACCME Accreditation Statement

The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement

The American Society of Addiction Medicine designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABPM Maintenance of Certification (MOC)

The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 2.5 LLSA credits towards ABPM MOC Part II requirements.

ABAM Transitional Maintenance of Certification (tMOC)

This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 2.5 AMA PRA Category 1 Credit(s)™ for completing this course.

Acknowledgement

Presented by ASAM, a member of the Collaborative on REMS Education (CO*RE), 10 interdisciplinary organizations working together to improve pain management and prevent adverse outcomes.

RPC Commercial Support Disclosure Statement

This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies. Please see this link for a listing of the member companies. This activity is intended to be fully compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the US Food & Drug Administration.

This course is not intended to advocate for the use of ER/LA Opioids, but to ensure proper education about safe prescribing practices should a medical provider determine that ER/LA Opioids are the best course of treatment.

The ASAM Fundamentals of Addiction Medicine 40-Hour Program is an innovative educational program empowering primary care and other providers to identify, treat, and/or refer patients at risk for or with addiction. Participants will learn how to recognize, screen, treat and refer patients with substance use disorders through 40 CME hours of interactive, case-based learning. This program is designed for healthcare professionals who received little addiction education during their medical training including physicians, clinicians, and other healthcare providers in primary care, emergency/urgent care, treatment centers and general psychiatry settings.

Why Participate

• Participants will receive official recognition and certificate for the completion of all 40 CME hours as laid out in the curriculum.
• Help patients that are already in your practice and be a part of the solution to the one of the nation’s deadliest epidemics
• Increase knowledge, skills and confidence for providers who may have received little or no addiction education during their medical training
• Learn how to integrate addiction medicine and payment models into your existing practice
• Connect with a community of colleagues and mentors for additional support with complex patients
• Experience content created specifically for primary care and other providers based on extensive needs-assessment
• Learn core competencies and knowledge needed to identify, treat, and refer patients with addiction to specialists when needed
• Earn a certificate of completion from ASAM upon completion of the 40-Hour CME Program

Curriculum Topics

• Attitudes towards addiction and treating patients with addiction
• Substance use disorders medications
• Neurobiology of addiction
• Screening, brief intervention, and referral to treatment (SBIRT)
• Motivational interviewing
• Medical and Psychiatric Co-morbidities
• Diagnosing substance use disorders
• Developing a treatment plan (including ASAM Criteria)
• Special populations (such as adolescents, pregnant women, etc)
• Referral to specialists

Program Activities

The ASAM Fundamentals of Addiction Medicine 40-Hour CME Program is comprised of five activities. All activities align with the nine identified addiction medicine competencies for primary care providers. ASAM has also gathered a collection of resources and tools reviewed by experts related to various topics of addiction medicine and working with patients at risk for or with substance use disorders (SUD) to supplement participant’s learning.   

Registration to the program includes the online version of all activities. Participants may elect to complete activities in a live, in-person format when available to fulfill program requirements.  Additional fees may apply for live-in-person events. Registration fees for the full-price, 8-hour live workshop will be credited towards the overall price of the ASAM Fundamentals of Addiction Medicine 40-Hour Program for new participants.

Program Competencies

The ASAM Fundamentals of Addiction Medicine 40-Hour Program seeks to help learners achieve nine identified competencies in the addiction medicine field. 

1. Interact with patients and professional colleagues so as to display professionalism in all activities, by demonstrating commitment to the health and well-being of individuals and society through ethical practice, profession-led regulation, and high personal standards of behavior.
2. Identify their feelings and attitudes that promote or prevent therapeutic responses to their patients with substance use disorders.
3. Understand the addictive disorders as developmental biopsychosocial disorders.
4. Take an evidence-based approach to detecting substance use disorders. 
5. Respond to positive substance use screening results with brief counseling strategies, appropriate to the patient’s readiness to change.
6. Use motivational interviewing with patients ambivalent about changing their substance use behavior.
7. Conduct a biopsychosocial and developmental ambulatory assessment of an adult with a suspected SUD to match the patient to an appropriate level of care.
8. List the indications, contraindications and duration of treatment of evidence based pharmacotherapy for alcohol, tobacco, and opioid use disorders and refer patient to specialty care where appropriate. 
9. Reflect on the role of behavioral interventions for patients and families including formal intensive ambulatory and inpatient treatment and informal programs such as mutual aid groups in the recovery process for patients in their practice/ communities.

The 40 hour CME curriculum is structured around these nine competencies, of which each competency has several learning objectives. Activities in the curriculum will align with at least one of the learning objectives.

If you experience any difficulties, please feel free to call the ASAM office at 301-656-3920 or email education@asam.org .

Note:  This program is for providers who are seeking additional knowledge about addiction medicine. This is not a certification or designed to prepare providers for certification exams. Providers interested in becoming an ABMS certified Addiction Specialist should go to www.abpm.org and/or learn about Addiction Fellowship programs at https://www.addictionmedicinefoundation.org/.

Why Participate?

Participants are saying....

• “This is probably the best post-graduate training I've ever done…The webinar format was engaging and educational. I greatly appreciate the opportunity to have involved at that level.” – MD, Massachusetts

• “Appreciate your effort to organize the training. It was a great experience. I'd definitely recommend this to my primary care colleagues.” – MD, Maryland

• “…living in the Northeast, I’m afraid I get very provincial so it’s been really interesting to hear everybody…but it’s the across the country responses that have been so helpful.” – MD, Massachusetts

• “Living in Alaska, the resources for substance abuse treatment is probably not as diversified as in other areas…so this clinic has been valuable to me… providing the information and talking, collaborating with other professions in the field to help provide the best care of the patients.” – NP, Alaska

Extensive Development from Experts.... 

The ASAM Fundamentals 40-Hour Program was developed over multiple years, beginning in 2013. ASAM’s committee of experts created, evaluated, and revised the Fundamentals program continuously to ensure providers received the highest quality, most up-to-date  education.

Competency-Based Program Activities...

The ASAM Fundamentals of Addiction Medicine 40-Hour Program is comprised of five components. All components and activities align with the nine identified addiction medicine competencies for primary care providers. ASAM has also gathered a collection of resources and tools reviewed by experts related to various topics of addiction medicine and working with patients at risk for or with substance use disorders (SUD) to supplement participant’s learning.   

Positive Outcomes for Participants' Practice...

Some of the most commonly reported changes as a result of the ASAM Fundamentals 40-Hour Program were:

• Change in patient treatment plans
• Change in approach to patients with SUDs
• More frequent screening, e.g. screening all patients at least annually.
• More use of screening tools or use of different screening tools.
• More or better use of SBIRT
• More or better use of MI techniques
• Increased confidence in treating patients with addiction

ASAM Fundamentals of Addiction Medicine Workshop Planning Committee

ASAM CME Committee

Commercial Interest Definition

A commercial interest is any entity producing, marketing, re-selling or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

Agency Support

ASAM thanks the Agency for Healthcare Research and Quality, an agency of the U.S. Department of Health and Human Services, for their support of the current Fundamentals of Addiction Medicine ECHO (FAME) series through grant number R18HS025067. 

Disclosure of Commercial Support

The American Society of Addiction gratefully acknowledges the support of the following companies in the development of The ASAM Fundamentals of Addiction Medicine Program.

Indivior provided an unrestricted educational grant to assist with the development, implementation and evaluation of this Fundamentals Program. 

Accreditation Council for Continuing Medical Education (ACCME)

The American Society of Addiction Medicine has been awarded the highest level of Accreditation with Commendation by the Accreditation Council for Continuing Medical Education (ACCME) as a provider of continuing medical education (CME) for physicians. Accreditation in the ACCME System seeks to assure the medical community and the public that ASAM delivers education that is relevant to clinicians’ needs, evidence-based, evaluated for its effectiveness, and independent of commercial influence. 

The ACCME System employs a rigorous process for evaluating institutions' CME programs according to standards that reflect the values of the educator community and aim to accelerate learning, inspire change, and champion improvement in healthcare. Through participation in accredited CME, clinicians and teams drive improvement in their practice and optimize the care, health, and wellness of their patients.

Please see individual sessions for accreditation information for specific offerings. 

The misuse of extended-release and long-acting (ER/LA) opioids is a major public health problem. Centers for Disease Control and Prevention reported the following:

• From 2000 to 2015 more than half a million people died from drug overdoses.
• 91 Americans die every day from an opioid overdose.

The CO*RE/ASAM Pain Management and Opioids: Balancing Risks and Benefits addresses the opioid public health crisis. This comprehensive course was developed by renowned experts from Collaborative for REMS Education (CO*RE) and incorporates all six units outlined in FDA blueprint for safe opioid prescribing. The updated course also provides necessary context for safe opioid prescribing by discussing biopsychosocial aspects of pain, the newest clinical guidelines on the treatment of chronic pain, and state policies about prescribing opioids.

Learners will be able to:

• Accurately assess patients with pain for consideration of an opioid trial
• Establish realistic goals for pain management and restoration of function
• Initiate opioid treatment (IR and ER/LA) safely and judiciously, maximizing efficacy while minimizing risks
• Monitor and re-evaluate treatment continuously; discontinue safely when appropriate
• Counsel patients and caregivers about use, misuse, abuse, diversion, and overdose
• Educate patients about safe storage and disposal of opioids
• Demonstrate working knowledge and ability to access general and specific information about opioids, especially those used in your practice.

CME Information and Disclosure Listing

The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. ASAM has been awarded the highest level of Accreditation with Commendation by the ACCME as a provider of continuing medical education.

The American Society of Addiction Medicine designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In accordance with the disclosure policies of the American Society of Addiction Medicine (ASAM) and the Accreditation Council for Continuing Medical Education (ACCME), the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the Medical Education Council, the CME Committee, program planning committees and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of the activity. All program planning committee members and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The ASAM CME Committee has reviewed these disclosures and determined that the program planning committee and faculty relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

ASAM CME Committee

Program Planning Committee

Faculty

ASAM CME Committee Reviewers

ASAM Medical Education Council

Acknowledgement

Presented by ASAM, a member of the Collaborative on REMS Education (CO*RE), 10 interdisciplinary organizations working together to improve pain management and prevent adverse outcomes.

RPC Commercial Support Disclosure Statement

This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies. Please see this link for a listing of the member companies. This activity is intended to be fully compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the US Food & Drug Administration.

This course is not intended to advocate for the use of ER/LA Opioids, but to ensure proper education about safe prescribing practices should a medical provider determine that ER/LA Opioids are the best course of treatment.

This webinar helps build knowledge of The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document, which guides provider decisions about drug testing, as no universal standard exists today. It will allow providers, patients and their families, healthcare administrators, and payers determine clearly what is appropriate practice and what is considered outside the realm of appropriate practice in regard to drug testing in clinical addiction medicine. This webinar is primarily intended for addiction specialists and all providers utilizing drug testing in the context of the identification, diagnosis, treatment, and monitoring of patients with, or at risk for, addiction. It will also be useful for physicians and other providers concerned about the possibility of addiction in their patient population.

Upon completion of this activity, participants should be able to:
-Recognize the importance of the guidance needed around drug testing today
-Identify the fundamental components of drug testing in a clinical setting
-Summarize the document's recommendations and discuss how they should be used in practice
-Address common clinical questions around drug testing in a clinical setting

Welcome to The ASAM Treatment of Opioid Use Disorder Course. This course provides the 8 hours of education needed to receive a waiver to prescribe buprenorphine in an office-based setting. More information on waiver requirements can be found on the SAMHSA website.

To begin the online portion of the course, please log in to your right and locate the box that says Module 1. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password.

This 8-hour online course combines modules from our blended course and Video On-Demand captured on October 5, 2016 in Washington, DC.

All online modules and quizzes must be completed before moving on to Video On-Demand. Detailed instructions for completing the online portion of the course can be found under the tab titled "Course Instructions."

After completing the online modules, Videos On-Demand, corresponding quizzes, and applicable evaluations, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.

Note: Resident & Fellow ASAM Members (in training) receive complimentary access to the 8-hour online ASAM Treatment of Opioid Use Disorder Course. Click here to become a member. Please note membership approval requires up to two business days.

Overview of Legislation

Physicians

The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

Apply

• Fill out the Waiver Notification Form on SAMHSA’s website.
• Submit copies of your training certificate(s) to SAMHSA by email: infobuprenorphine@samhsa.hhs.gov or fax: 301.576.5237.

SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

The ASAM National Practice Guidelines for the Use of Medications in the Treatment of Addiction Involving Opioid Use: Click here to view ASAM's newly released National Practice Guideline.

Prescribers Clinical Support System for Medication Assisted Treatment - A national training and mentoring project developed in response to the prescription opioid misuse epidemic and the availability of newer pharmacotherapies to address opioid dependence.

1. Mentoring for those providing care for opioid dependent individuals available at no cost to all interested providers. Click here.
2. Clinical Tools (clinical guidances, sample forms including: patient information, intake forms, treatment agreements, induction forms, TIPs and more). Click here.

SAMHSA Buprenorphine website: Click here to access SAMHSA's website for more information on buprenorphine prescribing. For questions on licensure, DEA-X number etc., please call 866-287-2728 or email info@buprenorphine.samhsa.gov.

DATA Physician Locator: Click here for SAMHSA's physician locator.

Waiver Notification Form: Click here for more information from SAMHSA on how to obtain a waiver and download a waiver notification form.

Agency for Healthcare Research and Quality: Click here for more information from the Agency for Healthcare Research and Quality.

National Institute on Drug Abuse: Click here to visit NIDA's website.

NIDA Buprenorphine Suite of Blending Products: Click here to access NIDA's buprenorphine training for multidisciplinary addiction professionals.

Drug Enforcement Administration: Click here to visit the DEA's website.

A Guide for Law Enforcement on Buprenorphine: Click here to read an article from Huffington Post on Methadone and Buprenorphine.

Handbook of Office-Based Buprenorphine Treatment of Opioid Dependence: Click here for a book by John A. Renner, Jr. and Petros Levounis on treating those with opioid dependence.

How To Fill Out Your NOI Form: Click here for a step-by-step video guide on how to fill out your NOI form. Provided by the American Academy of Addiction Psychiatry.

1. Locate the box on the right that says “Module 1" and click “View Web Content On-Demand"
2. Locate the box on the right that says “Certificate code" and enter the code given upon completion of Module 1 Part 1
3. Continue to Module 1 Part 2 and Module 1 Part 3
4. Once you have completed the entire module, locate the box called “Module 1 Quiz" and choose “Take Quiz"
5. After you have completed Module 1 Quiz, continue to modules 2 and 3
6. View the videos On-Demand and complete the associated quizzes
7. You will be required to pass all 7 quizzes with a grade of 70% or higher
8. When you complete all modules, quizzes, and evaluation you will be able to claim CME Credit through the ASAM e-Learning Center

CME Information and Disclosure Listing

Date of Release: January 15, 2017
Approved Through: December 31, 2018

ACCME Accreditation Statement

The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement

The American Society of Addiction Medicine designates this enduring material for a maximum of 8 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

The online enduring material will provide the required 8 hours needed to obtain the waiver to prescribe buprenorphine in office-based treatment of opioid use disorders.

This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

ASAM CME Committee

ASAM Buprenorphine Program Planning Committee

ASAM Buprenorphine Course Faculty

ASAM CME Committee Reviewers

At the conclusion of this activity, learners should be able to:

1. Apply for a waiver to prescribe buprenorphine to their patients with opioid use disorders
2. Identify and assess patients who are appropriate for treatment with medications
3. Have specific knowledge concerning the use of medications to manage patients with addiction involving opioid use
4. Discuss the psychiatric and medical co-morbidities associated with opioid addiction

1. Providers who wish to obtain a waiver to prescribe buprenorphine in office based treatment of opioid use disorders.
2. Clinicians and health care team members working with prescribers who prescribe buprenorphine in office based treatment of opioid use disorders.

The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.

When all 8 hours of the course have been completed, CME can be claimed in the e-Learning Center.

Friday, September 14, 2018 | 8:30 am - 1:00 pm

University of Colorado
Kettle Creek Room 108
1420 Austin Bluffs Pkwy
Colorado Springs, CO 80918

Hosted by IT MATTTRs 2

Online portion: Thursday, September 13, 2018

Welcome to the ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.

This is an 8-hour blended course combining 4 hours of online learning followed by 4 hours of live learning. The live portion of the course builds off the content delivered in the online portion. Course faculty are expecting you to come to the live course with the online portion completed. 

Getting started: To begin the online portion of the course, please log in to your right and locate the box that says Module 1. If you do not know your password, or you have forgotten it, select Forgot Password and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled Course Instructions.

Once you have completed the 4-hour online portion and the 4-hour live portion of the course, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.

Physicians

The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

Nurse Practitioners & Physician Assistants

Kentucky state code does not allow physician assistants to prescribe Schedule III Controlled Substances, so they can not become waivered to prescribe buprenorphine for addiction treatment.

On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

To qualify, NPs and PAs must: 

• Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
• Complete not less than 24 hours of appropriate education through a qualified provider
• Through other training or experience, demonstrate the ability to treat and manage OUD  
• If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

• 24-Hour Buprenorphine Curriculum Collaborative with the American Association of Nurse Practitioners (AANP) and the American Academy of Physician Assistants (AAPA)
• Clinical Tools, Inc
• Provider's Clinical Support System for Medication-Assisted Treatment (PCSS-MAT)

CME Information and Disclosure Listing

Date of Release: July 2015 

Approved Through: December 2019

The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. ASAM has been awarded the highest level of Accreditation with Commendation by the ACCME as a provider of continuing medical education.

The American Society of Addiction Medicine designates this enduring material for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Society of Addiction Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

ASAM CME Committee

ASAM Medical Education Council

Learners will be able to:

1. Apply for a waiver to prescribe buprenorphine to their patients with opioid use disorders
2. Identify and assess patients who are appropriate for treatment with medications
3. Have specific knowledge concerning the use of medications to manage patients with addiction involving opioid use
4. Discuss the psychiatric and medical co-morbidities associated with opioid addiction

1. Locate the box on the right that says “Module 1" and click “View Web Content On-Demand"
2. Locate the box on the right that says “Certificate code" and enter the code given upon completion of Module 1 Part 1
3. Continue to Module 1 Part 2 and Module 1 Part 3
4. Once you have completed the entire module, locate the box called “Module 1 Quiz" and choose “Take Quiz"
5. After you have completed Module 1 Quiz, continue to modules 2 and 3
6. You will be required to pass all 3 Module Quizzes with a grade of 70% or higher
7. Upon completion of both the 4 online hours and 4 live hours of the course, you will be able to claim CME Credit through the ASAM e-Learning Center

1. Physicians, Nurse Practitioners, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office based treatment of opioid use disorders.
2. Clinicians and health care team members working with physicians who prescribe buprenorphine in office based treatment of opioid use disorders.

The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.

Apply

• Fill out the Waiver Notification Form on SAMHSA’s website.
• Submit copies of your training certificate(s) to SAMHSA by email: infobuprenorphine@samhsa.hhs.gov or fax: 301.576.5237.

SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs and PAs from prescribing these medications even if Federal law allows it.

Apply

• Fill out the Waiver Notification Form on SAMHSA’s website.
• Submit copies of your training certificate(s) to SAMHSA by email: infobuprenorphine@samhsa.hhs.gov or fax: 301.576.5237.

SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

Qualify 

To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must: 

• Be licensed under state law to prescribe schedule III, IV, or V medications for pain
• Complete no less than 24 hours of appropriate education through a qualified provider
• Through other training or experience, demonstrate the ability to treat and manage OUD
• If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

Addiction assessment is in a sorry state of affairs – there's literally no standard model. Counselors use an approach that might charitably be called “intuitive". As a result, managed care utilization review nurses keep demanding more data from treatment providers – and let the telephone tag begin. Then, there is the problem of proprietary medical necessity criteria, which gives managed care companies rampant control of access to care on the basis of cost, not quality. METHOD: ASAM began addressing this with the publication of its Patient Placement Criteria, beginning in 1991. After 20 years of research, over $8 million of research and validation, and support from SAMHSA, ASAM is releasing CONTINUUM – The ASAM Criteria Decision Engine™ to the entire US treatment field. This workshop will provide the practical explanation, background, and interview experience to help active clinicians and program administrators understand how to organize, introduce and use this new clinical standard for success. The workshop will review counselor and patient evaluations from the alpha, beta and national demonstration projects. RESULTS: Attendees will review recent findings that CONTINUUM's decision engine can effectively revolutionize or even eliminate telephone prior authorizations and utilization review, as predicted by a Harvard Business School study and as currently being considered by states and county Medicaid systems across the U.S. The Workshop will review findings from a national survey of state requirements of the ASAM Criteria (more than 30 require or endorse it) and which states, counties, managed care companies and healthcare systems have shown interest in or have already begun adopting CONTINUUM™. A tour of the tool will demonstrate the counselor-ready structured interview, the intricate branched-chain algebraic decision tree that implements every adult admission criteria decision rule in the current 2013 ASAM textbook, and how CONTINUUM finally standardizes medical necessity admissions criteria. The Workshop will explain how to use CONTINUUM to meet the new requirements of the federal Parity Act for publicly available medical necessity criteria and to meet the summer 2015 federal Medicaid specifications for state Medicaid 1115 Waivers, requiring independent, external third party review of all substance use disorder placements. DISCUSSION: Through the Workshop, attendees will gain their own perception of the software's ease of use, learning curve, impact on the clinical assessment process and impact on managed care reimbursement – with both public and commercial payers. Attendees will learn how treatment systems were able to implement CONTINUUM across all adult levels of care, even achieving mandated use across all clinicians. The discussion will examine the practical issues of HIPAA and 42cfr data privacy. Finally, attendees will assess the software's potential for nationwide adoption for addiction treatment evaluation, placement and periodic re-evaluation. This includes consideration of its potential for: reforming or eliminating telephonic prior authorization and utilization review, integrating with electronic health records, and establishing a national addiction patient clinical registry.

Focus Session Proposal:

Overview of Legislation

Physicians

The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

Nurse Practitioners & Physician Assistants

On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

To qualify, NPs and PAs must: 

• Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
• Complete not less than 24 hours of appropriate education through a qualified provider
• Through other training or experience, demonstrate the ability to treat and manage OUD  
• If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

• 24-Hour Buprenorphine Curriculum Collaborative with the American Association of Nurse Practitioners (AANP) and the American Academy of Physician Assistants (AAPA)
• Clinical Tools, Inc
• Provider's Clinical Support System for Medication-Assisted Treatment (PCSS-MAT)

Apply

• Fill out the Waiver Notification Form on SAMHSA’s website.
• Submit copies of your training certificate(s) to SAMHSA by email: infobuprenorphine@samhsa.hhs.gov or fax: 301.576.5237.

SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs and PAs from prescribing these medications even if Federal law allows it.

Apply

• Fill out the Waiver Notification Form on SAMHSA’s website.
• Submit copies of your training certificate(s) to SAMHSA by email: infobuprenorphine@samhsa.hhs.gov or fax: 301.576.5237.

SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

Qualify 

To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must: 

• Be licensed under state law to prescribe schedule III, IV, or V medications for pain
• Complete no less than 24 hours of appropriate education through a qualified provider
• Through other training or experience, demonstrate the ability to treat and manage OUD
• If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

CME Information and Disclosure Listing

Date of Release: July 2015
Approved Through: July 2018

The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Society of Addiction Medicine designates this enduring material for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

The American Society of Addiction Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

The combined online enduring material and live activity will provide the required 8 hours needed to obtain the waiver to prescribe buprenorphine in office-based treatment of opioid use disorders.

This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

ASAM CME Committee

ASAM Buprenorphine Program Planning Committee

ASAM Buprenorphine Course Faculty

ASAM CME Committee Reviewers

Learners will be able to:

1. Apply for a waiver to prescribe buprenorphine to their patients with opioid use disorders
2. Identify and assess patients who are appropriate for treatment with medications
3. Have specific knowledge concerning the use of medications to manage patients with addiction involving opioid use
4. Discuss the psychiatric and medical co-morbidities associated with opioid addiction

1. Locate the box on the right that says “Module 1" and click “View Web Content On-Demand"
2. Locate the box on the right that says “Certificate code" and enter the code given upon completion of Module 1 Part 1
3. Continue to Module 1 Part 2 and Module 1 Part 3
4. Once you have completed the entire module, locate the box called “Module 1 Quiz" and choose “Take Quiz"
5. After you have completed Module 1 Quiz, continue to modules 2 and 3
6. You will be required to pass all 3 Module Quizzes with a grade of 70% or higher
7. Upon completion of both the 4 online hours and 4 live hours of the course, you will be able to claim CME Credit through the ASAM e-Learning Center

1. Physicians, Nurse Practitioners, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office based treatment of opioid use disorders.
2. Clinicians and health care team members working with physicians who prescribe buprenorphine in office based treatment of opioid use disorders.

The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.